Physician profile
Eric Karl Winter
NPI 1851482210
$1,097.11
in general payments reported to CMS, 2019-2025
13 companies · $50.03 in 2025
The $50.03 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.97 · 2020: $71.21 · 2021: $369 · 2022: $305 · 2023: $179 · 2024: $31.80 · 2025: $50.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $361.73 | 2021-2025 | Austedo, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $205.06 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $140.60 | 2019-2022 | |
| Corium, LLC | $68.54 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $53.86 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $52.47 | 2021-2023 | Ingrezza |
| Abbvie INC. | $48.35 | 2021 | |
| Allergan, INC. | $42.32 | 2019-2020 | |
| Lundbeck LLC | $38.01 | 2021-2022 | |
| Alkermes, INC. | $37.87 | 2021 | |
| Vanda Pharmaceuticals INC. | $19.56 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.55 | 2021 | |
| Indivior INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.